3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Breast Neoplasms
83
Neoplasm Metastasis
7
Neoplasms
6
Sarcoma
4
Squamous Cell Carcinoma of Head and Neck
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Untreated Operable Early Breast Cancer
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Somatostatinoma
1
Solid Tumors
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Interventions
Imatinib Mesylate
41
Sunitinib
17
nilotinib
12
regorafenib
10
ripretinib
6
avapritinib
6
Leucovorin
3
Ipilimumab
3
Gemcitabine
3
Dasatinib
3
CTLA-4 Antigen
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
Paclitaxel
2
Oxaliplatin
2
Midazolam
2
Irinotecan
2
Fluorouracil
2
Floxuridine
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
Biopsy, Fine-Needle
2
Bevacizumab
2
vatalanib
1
umbralisib
1
trametinib
1
tinostamustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Stromal Tumors
×
palbociclib
×
Clear all
NCT01907607
2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2
Completed
29 enrolled
8 charts